Skip to main navigation

About
- Team
- Contact
Research & Development
Pipeline
- RMC-4630
- Mutant RAS
- SOS1
- RMC-5552
Investors
Careers

Press Releases

Press Releases

Year

May 9, 2022

Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress

April 21, 2022

Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022

March 9, 2022

Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022

March 1, 2022

Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

February 28, 2022

Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

February 22, 2022

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022

February 3, 2022

Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

January 11, 2022

Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference

November 24, 2021

Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Next page
Last page

Displaying 1 - 10 of 79

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2022 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063
CCPA Notice | Privacy Policy

Search Investor Relations